Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
511 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Malignant Mesothelioma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma - Pipeline Review, H1 2017, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape. Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 30, 27, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 7 and 6 molecules, respectively. Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology). - The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 10 Global Markets Direct Report Coverage 10 Malignant Mesothelioma - Overview 11 Malignant Mesothelioma - Therapeutics Development 12 Pipeline Overview 12 Pipeline by Companies 13 Pipeline by Universities/Institutes 18 Products under Development by Companies 19 Products under Development by Universities/Institutes 24 Malignant Mesothelioma - Therapeutics Assessment 25 Assessment by Target 25 Assessment by Mechanism of Action 30 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Malignant Mesothelioma - Companies Involved in Therapeutics Development 39 Aduro BioTech Inc 39 Advantagene Inc 39 Amphera BV 40 AnGes MG Inc 40 arGEN-X BV 41 ArQule Inc 41 AVEO Pharmaceuticals Inc 42 Bayer AG 42 Biogen Inc 43 Bionomics Ltd 43 Biotecnol Ltd 44 Boehringer Ingelheim GmbH 44 Boston Biomedical Inc 45 Bristol-Myers Squibb Company 45 Calithera Biosciences Inc 46 CanBas Co Ltd 46 CBT Pharmaceuticals Inc 47 Concordia International Corp 47 Eagle Pharmaceuticals Inc 48 Eisai Co Ltd 48 Eli Lilly and Company 49 EnGeneIC Ltd 49 EpiZyme Inc 50 F. Hoffmann-La Roche Ltd 50 Five Prime Therapeutics Inc 51 Genelux Corp 51 GlaxoSmithKline Plc 52 Horizon Pharma Plc 52 Inventiva 53 Juno Therapeutics Inc 53 Karyopharm Therapeutics Inc 54 MacroGenics Inc 54 MedImmune LLC 55 Merck & Co Inc 55 Merck KGaA 56 Millennium Pharmaceuticals Inc 56 MolMed SpA 57 Morphotek Inc 57 Novartis AG 58 Ono Pharmaceutical Co Ltd 59 OSE Immunotherapeutics 59 Oxford BioMedica Plc 60 Pharma Mar SA 60 Philogen SpA 61 Polaris Pharmaceuticals Inc 61 Progenra Inc 62 Seattle Genetics Inc 62 Sellas Inc 63 Targovax ASA 63 TRACON Pharmaceuticals Inc 64 TREAT U SA 64 UbiVac LLC 65 VasGene Therapeutics Inc 65 Verastem Inc 66 Virttu Biologics Ltd 66 Vyriad Inc 67 Y's Therapeutics Co Ltd 67 Malignant Mesothelioma - Drug Profiles 68 (epirubicin + staurosporine) - Drug Profile 68 alisertib - Drug Profile 69 amatuximab - Drug Profile 75 anetumab ravtansine - Drug Profile 78 ARGX-110 - Drug Profile 81 atezolizumab - Drug Profile 86 AV-203 - Drug Profile 103 avelumab - Drug Profile 106 bevacizumab - Drug Profile 115 BG-00001 - Drug Profile 127 birabresib - Drug Profile 128 BMS-986148 - Drug Profile 131 BNC-105 - Drug Profile 132 brentuximab vedotin - Drug Profile 138 CB-839 - Drug Profile 165 CBP-501 - Drug Profile 174 CBT-501 - Drug Profile 177 Cellular Immunotherapy for Oncology - Drug Profile 178 Cellular Immunotherapy to Target Mesothelin for Malignant Pleural Mesothelioma and Advanced Leukemia - Drug Profile 179 Cellular Immunotherapy to Target Mesothelin for Oncology - Drug Profile 180 Cellular Immunotherapy to Target WT1 for Oncology - Drug Profile 181 cisplatin - Drug Profile 182 CRS-207 - Drug Profile 183 CSG-MESO - Drug Profile 190 defactinib hydrochloride - Drug Profile 191 DFP-10825 - Drug Profile 199 doxorubicin hydrochloride - Drug Profile 200 DPV-001 - Drug Profile 201 durvalumab - Drug Profile 203 durvalumab + tremelimumab - Drug Profile 217 E-7449 - Drug Profile 223 emactuzumab - Drug Profile 224 enoblituzumab - Drug Profile 225 ESK-1 - Drug Profile 228 FL-118 - Drug Profile 229 FP-1039 - Drug Profile 232 galinpepimut-S - Drug Profile 236 ganetespib - Drug Profile 240 GEN-0101 - Drug Profile 254 Gene Therapy for Glioblastoma and Mesothelioma - Drug Profile 256 Gene Therapy for Malignant Pleural Effusion and Solid Tumors - Drug Profile 257 Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile 258 GLONC-1 - Drug Profile 259 GSK-2256098 - Drug Profile 263 GSK-3359609 - Drug Profile 265 HSV-1716 - Drug Profile 266 HXR-9 - Drug Profile 270 iCasp9M28z - Drug Profile 271 interferon gamma-1b - Drug Profile 272 ipilimumab + nivolumab - Drug Profile 277 JTCR-016 - Drug Profile 281 KPT-251 - Drug Profile 283 KPT-276 - Drug Profile 284 LEU-001 - Drug Profile 285 lurbinectedin - Drug Profile 286 LY-3023414 - Drug Profile 294 MesoCancerVac - Drug Profile 296 MesoCART - Drug Profile 297 MGD-009 - Drug Profile 298 Monoclonal Antibody Conjugate to Target Mesothelin for Malignant Mesothelioma - Drug Profile 300 Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile 301 MTG-201 - Drug Profile 303 MTG-202 - Drug Profile 305 napabucasin - Drug Profile 306 NGR-hTNF - Drug Profile 314 nintedanib - Drug Profile 320 nivolumab - Drug Profile 331 Oncolytic Virus for Malignant Pleural Mesothelioma - Drug Profile 372 Oncolytic Virus to Target CD46 and SLC5A5 for Malignant Pleural Mesothelioma - Drug Profile 373 ONCOS-102 - Drug Profile 374 OSE-2101 - Drug Profile 377 Oshadi D + Oshadi R - Drug Profile 380 OXB-301 - Drug Profile 381 P-0005091 - Drug Profile 385 pegargiminase - Drug Profile 386 pembrolizumab - Drug Profile 395 pemetrexed disodium - Drug Profile 443 porfimer sodium - Drug Profile 444 rAd-IFN - Drug Profile 446 RG-7787 - Drug Profile 449 S-588210 - Drug Profile 451 Small Molecule for Malignant Mesothelioma and Asbestosis - Drug Profile 452 Small Molecule for Oncology - Drug Profile 453 Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Metastatic Lung Cancer - Drug Profile 454 TargomiRs - Drug Profile 455 tazemetostat - Drug Profile 457 TB-535 - Drug Profile 466 Teleukin - Drug Profile 467 tivantinib - Drug Profile 469 trabectedin - Drug Profile 475 TRC-102 - Drug Profile 482 Vaccine to target Mesothelin for Mesothelioma and Ovarian Cancer - Drug Profile 484 Vaccine to Target WT1 for Oncology - Drug Profile 485 Vas-01 - Drug Profile 486 YS-110 - Drug Profile 488 Malignant Mesothelioma - Dormant Projects 490 Malignant Mesothelioma - Discontinued Products 492 Malignant Mesothelioma - Product Development Milestones 493 Featured News & Press Releases 493 Appendix 504 Methodology 504 Coverage 504 Secondary Research 504 Primary Research 504 Expert Panel Validation 504 Contact Us 504 Disclaimer 505
List of Tables
Number of Products under Development for Malignant Mesothelioma, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Malignant Mesothelioma - Pipeline by Aduro BioTech Inc, H1 2017 Malignant Mesothelioma - Pipeline by Advantagene Inc, H1 2017 Malignant Mesothelioma - Pipeline by Amphera BV, H1 2017 Malignant Mesothelioma - Pipeline by AnGes MG Inc, H1 2017 Malignant Mesothelioma - Pipeline by arGEN-X BV, H1 2017 Malignant Mesothelioma - Pipeline by ArQule Inc, H1 2017 Malignant Mesothelioma - Pipeline by AVEO Pharmaceuticals Inc, H1 2017 Malignant Mesothelioma - Pipeline by Bayer AG, H1 2017 Malignant Mesothelioma - Pipeline by Biogen Inc, H1 2017 Malignant Mesothelioma - Pipeline by Bionomics Ltd, H1 2017 Malignant Mesothelioma - Pipeline by Biotecnol Ltd, H1 2017 Malignant Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H1 2017 Malignant Mesothelioma - Pipeline by Boston Biomedical Inc, H1 2017 Malignant Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H1 2017 Malignant Mesothelioma - Pipeline by Calithera Biosciences Inc, H1 2017 Malignant Mesothelioma - Pipeline by CanBas Co Ltd, H1 2017 Malignant Mesothelioma - Pipeline by CBT Pharmaceuticals Inc, H1 2017 Malignant Mesothelioma - Pipeline by Concordia International Corp, H1 2017 Malignant Mesothelioma - Pipeline by Eagle Pharmaceuticals Inc, H1 2017 Malignant Mesothelioma - Pipeline by Eisai Co Ltd, H1 2017 Malignant Mesothelioma - Pipeline by Eli Lilly and Company, H1 2017 Malignant Mesothelioma - Pipeline by EnGeneIC Ltd, H1 2017 Malignant Mesothelioma - Pipeline by EpiZyme Inc, H1 2017 Malignant Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Malignant Mesothelioma - Pipeline by Five Prime Therapeutics Inc, H1 2017 Malignant Mesothelioma - Pipeline by Genelux Corp, H1 2017 Malignant Mesothelioma - Pipeline by GlaxoSmithKline Plc, H1 2017 Malignant Mesothelioma - Pipeline by Horizon Pharma Plc, H1 2017 Malignant Mesothelioma - Pipeline by Inventiva, H1 2017 Malignant Mesothelioma - Pipeline by Juno Therapeutics Inc, H1 2017 Malignant Mesothelioma - Pipeline by Karyopharm Therapeutics Inc, H1 2017 Malignant Mesothelioma - Pipeline by MacroGenics Inc, H1 2017 Malignant Mesothelioma - Pipeline by MedImmune LLC, H1 2017 Malignant Mesothelioma - Pipeline by Merck & Co Inc, H1 2017 Malignant Mesothelioma - Pipeline by Merck KGaA, H1 2017 Malignant Mesothelioma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 Malignant Mesothelioma - Pipeline by MolMed SpA, H1 2017 Malignant Mesothelioma - Pipeline by Morphotek Inc, H1 2017 Malignant Mesothelioma - Pipeline by Novartis AG, H1 2017 Malignant Mesothelioma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 Malignant Mesothelioma - Pipeline by OSE Immunotherapeutics, H1 2017 Malignant Mesothelioma - Pipeline by Oxford BioMedica Plc, H1 2017 Malignant Mesothelioma - Pipeline by Pharma Mar SA, H1 2017 Malignant Mesothelioma - Pipeline by Philogen SpA, H1 2017 Malignant Mesothelioma - Pipeline by Polaris Pharmaceuticals Inc, H1 2017 Malignant Mesothelioma - Pipeline by Progenra Inc, H1 2017 Malignant Mesothelioma - Pipeline by Seattle Genetics Inc, H1 2017 Malignant Mesothelioma - Pipeline by Sellas Inc, H1 2017 Malignant Mesothelioma - Pipeline by Targovax ASA, H1 2017 Malignant Mesothelioma - Pipeline by TRACON Pharmaceuticals Inc, H1 2017 Malignant Mesothelioma - Pipeline by TREAT U SA, H1 2017 Malignant Mesothelioma - Pipeline by UbiVac LLC, H1 2017 Malignant Mesothelioma - Pipeline by VasGene Therapeutics Inc, H1 2017 Malignant Mesothelioma - Pipeline by Verastem Inc, H1 2017 Malignant Mesothelioma - Pipeline by Virttu Biologics Ltd, H1 2017 Malignant Mesothelioma - Pipeline by Vyriad Inc, H1 2017 Malignant Mesothelioma - Pipeline by Y's Therapeutics Co Ltd, H1 2017 Malignant Mesothelioma - Dormant Projects, H1 2017 Malignant Mesothelioma - Dormant Projects, H1 2017 (Contd..1), H1 2017 Malignant Mesothelioma - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.